摘要
目的:探讨263例前列腺癌患者就诊情况及诊断治疗现状。方法:将我院近22年来263例前列腺癌患者的临床资料按年份1983～1992年,1993～1998年和1999～2004年分为3组,从就诊情况、诊断和治疗方面进行分析。结果:1999年～2004年6年间共收治180例,总例数是1983年～1992年的3.67倍,是1993年～1999年的5.29倍。近年来老龄化更加明显(!2=5.957,P=0.015)。前列腺特异抗原检测应用前后,患者的临床分期(!2=1.146,P=0.564)和肿瘤分级构成比(!2=6.696,P=0.153)无统计学差异。直肠指诊(DRE)、前列腺特异性抗原(PSA)和经直肠前列腺B超(TRUS)在前列腺癌的诊断中已占主导地位。根治性手术逐渐增多,采用内分泌治疗的患者仍占多数。结论:前列腺癌临床发病率有增高趋势,临床应用PSA检测后,患者年龄、临床分期和肿瘤分级没有明显下降。内分泌治疗仍占重要地位。
Objective： To approach the present situation for clinical visit, diagnosis and treatment of 263 cases with prostate cancer. Methods： The clinical data for 263 cases with prostatic carcinoma during recent 22 years were divided into 3 groups and were retrospectively analyzed. Results： In recent 6 years, 180 new cases have been diagnosed in our hospital. This was 3.67 times the general number of the cases in 1983-1992, and 5.29 folds that in 1993-1999. The aging trends in the patients with prostate cancer was obvious （X^2=5.957, P=0.015）. There was no statistical difference between the proportion of clinical stage （X^2=1.146, P=0.564） and the grade of tumor （X^2=6.696, P=0.153） before and after clinical use of PSA. The chief role of DRE, PSA and TRUS in diagnosis of prostate cancer have been established. Although the number of radical prostateetomy increased, patients receiving endocrine therapy were still in majority. Conclusions： The clinical incidence of prostatic cancer is markedly increasing in recent years. The age, clinical stage and tumor grade of prostate cancer do not decrease after clinical use of PSA. Androgen deprived treatment still have important role in clinical control of prostate cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第6期339-341,345,共4页
Chinese Journal of Clinical Oncology
关键词
前列腺肿瘤
癌
前列腺特异抗原
诊断
Tumor of prostate Carcinoma Prostate-specific antigen Diagnosis
